Sinopharm s Covid-19 vaccine remained active against S.Africa variant, effect reduced - lab study
The activity reduction “should be taken into account for its impact for the clinical efficacy of these vaccines”
Reuters
February 03, 2021
BEIJING:
Two Covid-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.
Hibbing, MN, USA / 93.9 WTBX
Feb 2, 2021 10:05 PM
BEIJING (Reuters) - Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.
03 February 2021 - 07:54 By Reuters The Sinopharm vaccine is approved in China for general public use and is also used in other countries, including the United Arab Emirates Image: REUTERS/Tingshu Wang
Two Covid-19 vaccines from Chinese companies, including Sinopharm, triggered immunity against a highly transmissible coronavirus variant first found in SA, but their effect appeared weaker, a small sample lab study showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the SA variant, their researchers said in a paper.
Two Covid-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.